Association of apolipoprotein E genotypes with prognosis in multiple sclerosis

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 10, 2011, Pages 1122-1130

  Tamam, Yusuf ^a   Tasdemir, N ^a   Yalman, M ^a   Tamam, B ^b  

^a DICLE UNIVERSITY   (Turkey)

^b Diyarbakir Devlet Hastanesi   (Turkey)

Author keywords

APOE; EDSS; Genotype; Multiple sclerosis; Prognosis

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEPHELOMETRY; POLYMERASE CHAIN REACTION; PROGNOSIS;

ADULT; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HUMANS; MALE; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 82455206148     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. SADIQ SA, MILLE J. Multiple sclerosis. In: Rowlaand RP (ed): Merritt's Textbook of Neurology. 9th edition. New York, Williams and Wilkins, 1994: pp. 804-825.
2. SANDBRINK R, HARTMANN T, MASTERS CL, BEYREUTHER K. Genes contributing to Alzheimer's disease. Mol Psychiatry 1996; 1: 27-40.
3. DUQUETTE P, PLEINES J, GIRARD M, CHAREST L, SENECAL-QUEVILLON M, MASSE C. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci 1992; 19: 466-471.
4. HENSIEK AE, SAWCER SJ, FEAKES R, DEANS J, MANDER A, AKESSON E, ROXBURGH R, CORADDU F, SMITH S, COMPSTON DA. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 184-187.
5. MIYATA M, SMITH JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14: 55-61.
6. WEATHERBY SJ, MANN CL, DAVIES MB, CARTHY D, FRYER AA, BOGGILD MD, YOUNG C, STRANGE RC, OLLIER W, HAWKINS CP. Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis. Mult Scler 2000; 6: 32-36.
7. WEATHERBY SJ, MANN CL, FRYER AA, STRANGE RC, HAWKINS CP, STEVENSON VL, LEARY SM, THOMPSON AJ. No association between the APOE epsilon4 allele and outcome and susceptibility in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 532.
8. GAILLARD O, GERVAIS A, MEILLET D, PLASSART E, FONTAINE B, LYON-CAEN O, DELATTRE J, SCHULLER E. Apolipoprotein E and multiple sclerosis: a biochemical and genetic investigation. J Neurol Sci 1998; 158: 180-186.
9. MCDONALD WI, COMPSTON A, EDAN G, GOODKIN D, HARTUNG HP, LUBLIN FD, MCFARLAND HF, PATY DW, POLMAN CH, REINGOLD SC, SANDBERG-WOLLHEIM M, SIBLEY W, THOMPSON A, VAN DEN NOORT S, WEINSHENKER BY, WOLINSKY JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
10. EBERS GC, BULMAN DE, SADOVNICK AD, PATY DW, WARREN S, HADER W, MURRAY TJ, SELAND TP, DUQUETTE P, GREY T, et al. A population-based study of multiple sclerosis in twins. N Engl J Med 1986; 315: 1638-1642.
11. MUMFORD CJ, WOOD NW, KELLAR-WOOD H, THORPE JW, MILLER DH, COMPSTON DA.The British Isles survey of multiple sclerosis in twins. Neurology 1994; 44: 11-15.
12. SADOVNICK AD, ARMSTRONG H, RICE GP, BULMAN D, HASHIMOTO L, PATY DW, HASHIMOTO SA, WARREN S, HADER W, MURRAY TJ, et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993; 33: 281-285.
13. MULTIPLE SCLEROSIS: Its Impact from Childhood to Old Age. (Major Problems in Neurology Series /26). By Bauer HJ & Hanefeld FA. London, WB Saunders Co. Ltd., 1993.
14. DEAN G, AKSOY H, AKALIN T, MIDDLETON L, KYRIALLIS K. Multiple sclerosis in the Turkish- and Greek-speaking communities of Cyprus. A United Nations (UNHCR) Bicommunal Project. J Neurol Sci 1997; 145: 163-168.
15. BALLERINI C, CAMPANI D, ROMBOLÀ G, GRAN B, NACMIAS B, AMATO MP, SIRACUSA G, BARTOLOZZI L, SORBI S, MASSACESI L. Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. Neurosci Lett 2000; 296: 174-176.
16. EVANGELOU N, JACKSON M, BEESON D, PALACE J. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 67: 203-205.
17. FAZEKAS F, STRASSER-FUCHS S, KOLLEGGER H, BERGER T, KRISTOFERITSCH W, SCHMIDT H, ENZINGER C, SCHIEFERMEIER M, SCHWARZ C, KORNEK B, REINDL M, HUBER K, GRASS R, WIMMER G, VASS K, PFEIFFER KH, HARTUNG HP, SCHMIDT R. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 2001; 57: 853-857.
18. PINHOLT M, FREDERIKSEN JL, ANDERSEN PS, CHRISTIANSEN M. Apo E in multiple sclerosis and optic neuritis: the apo E-epsilon4 allele is associated with progression of multiple sclerosis. Mult Scler 2005; 11: 511-515.
19. CHAPMAN J, SYLANTIEV C, NISIPEANU P, KORCZYN AD. Preliminary observations on APOE epsilon4 allele and progression of disability in multiple sclerosis. Arch Neurol 1999; 56: 1484-1487.
20. CHAPMAN J, VINOKUROV S, ACHIRON A, KARUSSIS DM, MITOSEK-SZEWCZYK K, BIRNBAUM M, MICHAELSON DM, KORCZYN AD. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001; 56: 312-316.
21. ENZINGER C, ROPELE S, STRASSER-FUCHS S, KAPELLER P, SCHMIDT H, POLTRUM B, SCHMIDT R, HARTUNG HP, FAZEKAS F. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol 2003; 60: 65-70.
22. KANTARCI OH, HEBRINK DD, ACHENBACH SJ, PITTOCK SJ, ALTINTAS A, SCHAEFER-KLEIN JL, ATKINSON EJ, DE ANDRADE M, MCMURRAY CT, RODRIGUEZ M, WEINSHENKER BG. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology 2004; 62: 811-814.
23. SANTOS M, DO CARMO COSTA M, EDITE RIO M, JOSÉ SÁ M, MONTEIRO M, VALENÇA A, SÁ A, DINIS J, FIGUEIREDO J, BIGOTTE DE ALMEIDA L, VALONGUEIRO A, COELHO I, MATAMÁ MT, PINTO-BASTO J, SEQUEIROS J, MACIEL P. Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. Mult Scler 2004; 10: 153-157.
24. OLIVERI RL, CITTADELLA R, SIBILIA G, MANNA I, VALENTINO P, GAMBARDELLA A, AGUGLIA U, ZAPPIA M, ROMEO N, ANDREOLI V, BONO F, CARACCIOLO M, QUATTRONE A. APOE and risk of cognitive impairment in multiple sclerosis. Acta Neurol Scand 1999; 100: 290-295.
25. KOUTSIS G, PANAS M, KARADIMA G, MANDELLOS D, SFAGOS C, POTAGAS C, VASSILOPOULOS D. APOE genotypes in Greek multiple sclerosis patients: no effect on the MS Severity Score. J Neurol 2007; 254: 394-395.
26. AL-SHAMMRI S, FATANIA H, AL-RADWAN R, AKANJI AO. The relationship of APOE genetic polymorphism with susceptibility to multiple sclerosis and its clinical phenotypes in Kuwaiti Arab subjects. Clin Chim Acta 2005; 351: 203-207.
27. ZWEMMER JN, VAN VEEN T, VAN WINSEN L, VAN KAMP GJ, BARKHOF F, POLMAN CH, UITDEHAAG BM. No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis. Mult Scler 2004; 10: 272-277.
28. HØGH P, OTURAI A, SCHREIBER K, BLINKENBERG M, JØRGENSEN OS, RYDER L, PAULSON OB, SØRENSEN PS, KNUDSEN GM. Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult Scler 2000; 6: 226-230.
29. GUERRERO AL, BUENO V, HERNÁNDEZ MT, MARTÍN-SERRADILLA JI, CARRASCO E, CUADRADO I. Apolipoprotein E polymorphism as a predictor of progression of multiple sclerosis. Neurologia 2003; 18: 146-148.
30. FERRI C, SCIACCA FL, VEGLIA F, MARTINELLI F, COMI G, CANAL N, GRIMALDI LM. APOE epsilon2-4 and -491 polymorphisms are not associated with MS. Neurology 1999; 53: 888-889.
31. PIRTTILÄ T, HAANPÄÄ M, MEHTA PD, LEHTIMAKI T. Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster. Acta Neurol Scand 2000; 102: 94-98.
32. KRAFT GH, FREAL JE, CORYELL JK, HANAN CL, CHITNIS N. Multiple sclerosis: early prognostic guidelines. Arch Phys Med Rehabil 1981; 62: 54-58.
33. POTEMKOWSKI A. Optic neuritis as the initial manifestation of multiple sclerosis. Klin Oczna 2000; 102: 95-98.
34. WIKSTRÖM J, POSER S, RITTER G. Optic neuritis as an initial symptom in multiple sclerosis. Acta Neurol Scand 1980; 61: 178-185.
35. DE STEFANO N, BARTOLOZZI ML, NACMIAS B, ZIPOLI V, MORTILLA M, GUIDI L, SIRACUSA G, SORBI S, FEDERICO A, AMATO MP. Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch Neurol 2004; 61: 536-540.
36. MASTERMAN T, ZHANG Z, HELLGREN D, SALTER H, ANVRET M, LILIUS L, LANNFELT L, HILLERT J. APOE genotypes and disease severity in multiple sclerosis. Mult Scler 2002; 8: 98-103.
37. SAVETTIERI G, ANDREOLI V, BONAVITA S, CITTADELLA R, CALTAGIRONE C, FAZIO MC, GIRLANDA P, LE PIRA F, LIGUORI M, LOGROSCINO G, LUGARESI A, NOCENTINI U, REGGIO A, SALEMI G, SERRA P, TEDESCHI G, TOMA L, TROJANO M, VALENTINO P, QUATTRONE A. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J Neurol 2003; 250: 1094-1098.
38. SEDANO MI, CALMARZA P, PEREZ L, TREJO JM. No association of apolipoprotein E epsilon4 genotype with faster progression or less recovery of relapses in a Spanish cohort of multiple sclerosis. Mult Scler 2006; 12: 13-18.
39. RAMAGOPALAN SV, DELUCA GC, MORRISON KM, HERRERA BM, DYMENT DA, ORTON S, BIHOREAU MT, DEGENHARDT A, PUGLIATTI M, SADOVNICK AD, SOTGIU S, EBERS GC. No effect of APOE and PVRL2 on the clinical outcome of multiple sclerosis. J Neuroimmunol 2007; 186: 156-160.
40. GUERRERO AL, LAHERRÁN E, GUTIÉRREZ F, MARTÍN-POLO J, IGLESIAS F, ALCÁZAR C, PERALTA J, ROSTAMI P. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score. Acta Neurol Scand 2008; 117: 21-25.
41. VAN DER WALT A, STANKOVICH J, BAHLO M, TAYLOR BV, VAN DER MEI IA, FOOTE SJ, KILPATRICK TJ, RUBIO JP, BUTZKUEVEN H. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology 2009; 73: 1018-1025.
42. PORTACCIO E, GORETTI B, ZIPOLI V, NACMIAS B, STROMILLO ML, BARTOLOZZI ML, SIRACUSA G, GUIDI L, FEDERICO A, SORBI S, DE STEFANO N, AMATO MP. APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. Mult Scler 2009; 15: 1489-1494.
43. PORTACCIO E, ZIPOU V, GORETTI B, HAKIKI B, NACMIAS B, SIRACUSA G, SORBI S, AMATO MP. ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. Acta Neurol Scand 2009; 120: 439-441.
44. GHAFFAR O, REIS M, PENNELL N, O'CONNOR P, FEINSTEIN A. APOE epsilon4 and the cognitive genetics of multiple sclerosis. Neurology 2010; 74: 1611-1618.
45. SCHMIDT S, BARCELLOS LF, DESOMBRE K, RIMMLER JB, LINCOLN RR, BUCHER P, SAUNDERS AM, LAI E, MARTIN ER, VANCE JM, OKSENBERG JR, HAUSER SL, PERICAK-VANCE MA, HAINES JL; MULTIPLE SCLEROSIS GENETICS GROUP. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet 2002; 70: 708-717.
46. CARLIN C, MURRAY L, GRAHAM D, DOYLE D, NICOLL J. Involvement of apolipoprotein E in multiple sclerosis: absence of remyelination associated with possession of the APOE epsilon2 allele. J Neuropath Exp Neurol 2000; 59: 361-367.
47. FAZEKAS F, STRASSER-FUCHS S, SCHMIDT H, ENZINGER C, ROPELE S, LECHNER A, FLOOH E, SCHMIDT R, HARTUNG HP. Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 69: 25-28.
48. PARMENTER BA, DENNEY DR, LYNCH SG, MIDDLETON LS, HARLAN LM. Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms. Mult Scler 2007; 13: 25-32.
49. CARLSSON J, ARMSTRONG VW, REIBER H, FELGENHAUER K, SEIDEL D. Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin Chim Acta 1991; 196: 167-176.
50. GELMAN BB, RIFAI N, CHRISTENSON RH, SILVERMAN LM. Cerebrospinal fluid and plasma apolipoproteins in patients with multiple sclerosis. Ann Clin Lab Sci 1988; 18: 46-52.
51. RIFAI N, CHRISTENSON RH, GELMAN BB, SILVERMAN LM. Changes in cerebrospinal fluid IgG and apolipoprotein E indices in patients with multiple sclerosis during demyelination and remyelination. Clin Chem 1987; 33: 1155-1157.